Agilent Technologies, Inc. A
172.79
(0.05)
(0.03%)
as of 25 Sep
- Market cap
- $49.0B
- P/E
- 33.9×
Follow A
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Agilent Technologies, Inc. (A) Net margin
Agilent Technologies, Inc.'s net margin over the twelve months to 31 July 2026 was 19.5%, up 0.8 percentage points from fiscal 2025 (18.8%). Over the past ten years it has ranged from 6.43% (fiscal 2018) to 20.7% (fiscal 2019); the current reading is higher than 73% of that period. That is above the Diagnostics & Research industry median of −6.37% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 18.8% | (1.05) |
| FY2024 | 19.8% | 1.65 |
| FY2023 | 18.2% | (0.16) |
| FY2022 | 18.3% | (0.84) |
| FY2021 | 19.2% | 5.68 |
| FY2020 | 13.5% | (7.27) |
| FY2019 | 20.7% | 14.31 |
| FY2018 | 6.43% | (8.87) |
| FY2017 | 15.3% | 4.31 |
| FY2016 | 11.0% | 1.06 |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jul 2026 | 19.3% | 0.81 |
| Apr 2026 | 18.5% | 1.51 |
| Jan 2026 | 17.0% | (6.36) |
| Oct 2025 | 23.3% | 3.99 |
| 43 more quarters | Free account |
Against its own ten years
Low 6.43%
High 20.7%
Ten-year median
18.2%
Current reading's percentile
73
Net margin against peers
| Company | Net margin |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 25.0% |
| MTD Mettler-Toledo International, Inc. compare | 21.9% |
| A Agilent Technologies, Inc. | 19.5% |
| ILMN Illumina, Inc. compare | 18.4% |
| DGX Quest Diagnostics Incorporated compare | 9.15% |
| IQV IQVIA Holdings Inc. compare | 8.10% |
| WAT Waters Corporation compare | 3.59% |
| NTRA Natera, Inc. compare | −7.11% |
| GH Guardant Health, Inc. compare | −38.3% |
| Diagnostics & Research industry median | −6.37% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on A
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement